Even as weight-loss drugs such as Wegovy and Zepbound explode in popularity, many Americans struggle to afford them.
Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical ...
A new study is out that compares the effectiveness of two popular weight loss drugs, Wegovy and Zepbound. The study, which ...
Doctors say early obesity intervention can help prevent later health problems. But prescribing GLP-1s, such as Ozempic and ...
About 42% of U.S. adults are obese, the CDC says. GLP-1 medications have changed the picture for people hoping to reduce ...
The jump in prescription fills comes despite limited insurance coverage and high out-of-pocket costs for Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound.
It appears not all weight-loss drugs are created equal. The users of one drug report more weight loss comparted to another ...
Millions of Americans with obesity would be eligible to have popular weight-loss drugs like Wegovy or Ozempic covered by ...
Millions of Americans with obesity would be eligible to have popular drugs used for weight loss like Wegovy or Ozempic ...
(AP Photo/David J. Phillip, File)(David J. Phillip / ASSOCIATED PRESS) WASHINGTON — Millions of Americans with obesity would ...
such as Wegovy and Zepbound, has ushered in a new era in weight management. While these drugs can lead to significant weight loss, researchers and medical professionals have raised concerns about ...